Clinical Trial Update: A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of gemcitabine elaidate (CO-101) with cisplatin for solid tumors, including non-small cell lung cancer, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine Elaidate (CO-101) (gemcitabine elaidate)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Solid Tumor, Non-small-cell Lung Cancer | Phase 1 | Status: TERMINATED